In 2009 the Biotechnology Industry was Dominated by the Top 10 Companies
The Global Orthobiologics Market is Forecast to Reach $9.6 Billion in 2016 after Growing at a CAGR of 12% During 2009-2016
The Global Biologics Industry Has Grown More Rapidly Than the Global Pharmaceutical Industry
The Ulcerative Colitis Therapeutics Market is Projected to Show Reasonable Growth by 2015
Driven by a strong demand of biopharmaceuticals, vaccines and clinical trial materials; the global market for healthcare cold chain logistic services is expected to grow exponentially in the coming years.
Lantus is expected to be the most lucrative target for biosimilar manufacturers and account for 71% of the total biosimilar Insulin sales by 2020.
The volume penetration of biosimilars in the US will strongly depend upon the complexity of the molecule, the patient pool that it caters and the extent of savings it brings to payers and providers
Excluding Mabthera, Roche’s other brands will face biosimilar competition only after 2019. As a result, the company will suffer most of its brand erosion post-2020.
Biosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgrastim).
With the patents of all major monoclonal antibodies set to expire during 2015 - 2020, Biosimilar (or Follow-on) Monoclonal Antibodies are expected to represent the next big thing for generic manufacturers.
Page 1 of 2